December 29, 1976

Dr. Maxine F. Singer
Laboratory of Biochemistry and Metabolism
National Institute of Arthritis and Metabolic Disease
National Institute of Health
Bethesda, Maryland

Dear Dr. Singer:

This letter is to request your participation in a legislative hearing on the public health and safety implications of public and private recombinant DNA research in California. The hearings will be held under the joint aegis of the California Assembly Committee on Resources, Land Use, and Energy and the Assembly Committee on Health. They will commence Friday, January 21, 1977 in Sacramento, California, and will continue for three consecutive Fridays.

We have tentatively scheduled consideration of the NIH guidelines for the third hearing date, Friday, February 11, 1977 at 9:30 a.m. in Room 4202 of the state Capitol. In view of your thorough familiarity with the issue and your role as public spokesman for NIH, we would solicit your testimony as lead-off witness for that phase of the hearings.

Our purpose is to understand the nature and benefits of recombinant DNA and related forms of research, as well as the potential hazards. We are aware of the numerous disparate viewpoints held as to the actual level of public risk, if any, associated with the research. We intend to fully and responsibly explore this range of opinions so that the information we develop will be as accurate and complete as possible.
We would very much appreciate your participation and guidance.

Sincerely,

CHARLES WARREN, CHAIRMAN  
BARRY KEENE, CHAIRMAN  
Assembly Committee on Resources, Land Use, and Energy  
Assembly Committee on Health

By  

CHARLES WARREN

CW/cl

Wagstaff, ass't to Keene: prepared statement 20/1 outline guidelines approved.